Catalyst Pharmaceuticals Inc
Save
–
Market cap
23.13x
Current P/E
12.38x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type.
Similar securities
Based on sector and market capitalization
Report issue